Charles River Laboratories International In (CRL)

Impinj is a speculative stock but would be good to own if there's a pullback.

This is not the time to sell in a panic, Cramer says.

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at three upcoming investor conferences, including: Baird 2016 Global Healthcare Conference in New York on...

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a strategic partnership with the Milner Therapeutics Institute and Consortium.

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2016.

Trade-Ideas LLC identified Charles River Laboratories International In (CRL) as a new lifetime high candidate

Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2016 financial results on Wednesday, August 3 rd before the market opens.

The sharp declines seen across the healthcare sector could present buying opportunities in companies such as Aetna, HCA, Icon and Paraxel.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has acquired Blue Stream Laboratories, Inc.

Shares of Charles River Labs (CRL) fell this afternoon as Credit Suisse initiated coverage of the company with a 'neutral' rating.

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Jefferies 2016 Global Healthcare Conference in New York, New York on Wednesday, June 8 th, at 10:00 a.

Moderna Therapeutics, a clinical stage pioneer in the development of messenger RNA (mRNA) Therapeutics™ and Charles River Laboratories International, Inc.

Trade-Ideas LLC identified Charles River Laboratories International In (CRL) as a new lifetime high candidate

Trade-Ideas LLC identified Charles River Laboratories International In (CRL) as a new lifetime high candidate

Trade-Ideas LLC identified Charles River Laboratories International In (CRL) as a new lifetime high candidate

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2016.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a strategic partnership with BioMotiv, LLC, the therapeutic accelerator company associated with The Harrington Project for...

Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2016 financial results on Wednesday, May 4 th before the market opens.

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it has completed the previously announced acquisition of WIL Research for approximately $585 million in cash, subject to certain customary...

Trade-Ideas LLC identified Charles River Laboratories International In (CRL) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

The most recent short interest data has been released by the NASDAQ for the 03/01/2016 settlement date, which shows a 272,521 share increase in total short interest for Charles River Laboratories International Inc. , to 2,346,986, an increase of 13.14% since 02/12/2016.

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Raymond James 37 th Annual Institutional Investors Conference in Orlando, Florida on Tuesday, March 8 th, at 10:25 a.

Stocks with insider trader activity include CMS, CRL and LC

Trade-Ideas LLC identified Charles River Laboratories International In (CRL) as a "storm the castle" (crossing above the 200-day simple moving average on higher than normal relative volume) candidate

Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the fourth-quarter and full-year 2015 and provided guidance for 2016.

Stocks with insider trader activity include CRL, BID and RTN

Trade-Ideas LLC identified Charles River Laboratories International In (CRL) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate

Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2015 financial results and provide 2016 guidance on Wednesday, February 10th, before the market opens.